| 77.65 1.05 (1.37%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 92.62 | 1-year : | 96.46 |
| Resists | First : | 79.3 | Second : | 82.58 |
| Pivot price | 75.41 |
|||
| Supports | First : | 73.98 | Second : | 61.55 |
| MAs | MA(5) : | 75.78 |
MA(20) : | 76.37 |
| MA(100) : | 76.96 |
MA(250) : | 79.82 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 66.3 |
D(3) : | 39.2 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 89.73 | Low : | 72.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GILD ] has closed Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 77.78 - 78.09 | 78.09 - 78.41 |
| Low: | 75.43 - 75.76 | 75.76 - 76.09 |
| Close: | 77.11 - 77.68 | 77.68 - 78.27 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Fri, 01 Dec 2023
Crawford Investment Counsel Inc. Has $28.53 Million Holdings in ... - MarketBeat
Thu, 30 Nov 2023
Gilead's Leadership in Metastatic Breast Cancer Showcased With ... - Gilead Sciences
Wed, 29 Nov 2023
GILD Factor-Based Stock Analysis - Nasdaq
Fri, 24 Nov 2023
Is Gilead Sciences, Inc. (GILD) Stock Trading Below Fair Value? - InvestorsObserver
Fri, 24 Nov 2023
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR ... - Yahoo Finance
Tue, 21 Nov 2023
What is the Market's View on Gilead Sciences, Inc. (GILD) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 1,250 (M) |
| Shares Float | 1,240 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 86.8 (%) |
| Shares Short | 19,500 (K) |
| Shares Short P.Month | 20,240 (K) |
| EPS | 4.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.88 |
| Profit Margin | 21.4 % |
| Operating Margin | 38.5 % |
| Return on Assets (ttm) | 9.2 % |
| Return on Equity (ttm) | 26.9 % |
| Qtrly Rev. Growth | 0.1 % |
| Gross Profit (p.s.) | 17.29 |
| Sales Per Share | 21.91 |
| EBITDA (p.s.) | 9.39 |
| Qtrly Earnings Growth | 21.7 % |
| Operating Cash Flow | 8,400 (M) |
| Levered Free Cash Flow | 9,220 (M) |
| PE Ratio | 16.62 |
| PEG Ratio | 2.7 |
| Price to Book value | 4.34 |
| Price to Sales | 3.54 |
| Price to Cash Flow | 11.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|